Возможности коррекции высокой остаточной реактивности тромбоцитов на терапии дезагрегантами1

1. Brar SS, Ten Berg J, Marcucci R et al. Impact of platelet reactivity on clinical outcomes after pecutaneous coronary intervention a collaborative meta-analysis of individual participant data. 
J Am Coll Cardiol 2011; 58 (19): 1945–4.
2. Bonello L, Tantry US, Marcucci R. et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919–3.
3. Sibbing D, Morath T, Braun S et al. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost 2010; 103: 151–9.
4. Geisler T, Zurn Ch, Simonenko R et al. Early but not late stent thrombosis is influensed by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 2010; 31: 59–6.
5. Breet NJ, van Werkum JW, Bouman IIJ et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. J Am Med Assoc 2010; 303: 754–2.
6. Bliden KP, Di Chiara J, Looxman L et al. The association of cigarette smoking with enhanced plateled inhibition by clopidogrel. J Am Coll Cardiol 2008, 52: 531–3.
7. Desai NR, Mega JL, Jiang S et al. Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Col. Cardiol 2009; 53: 1273–8.
8. Beitleshees AL. March 29, 2012, www.thelancet.com.
9. Von Beckerath N, Rastrati A, Wiekzorek A et al. A double-blind, randomised study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 2007; 28: 1814–9.
10. Mehta SR, Bassand JP, Chrolavicians S et al. CURREN-OASIS 7 investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndrome. N Engl J Med 2010; 363: 930–2.
11. TRITON-TIMI 38 Investigators. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 2009; 30: 1753–3.
12. Hochholzer W, Trenk D, Bestehorn HP et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742–50.
13. Geisler T, Zurn Ch, Simonenko R et al. Early but not late stent thrombosis is influensed by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 2010; 31: 59–6.
14. Price MJ, Berger PB, Teirstein PS et al. GRAVITAS investigators. Standard – vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomised trial. J Am Med Assoc 2011; 305: 1097–05.
15. Lomonosova AA, Mazur NA, Zolozova EA et al. Residual platelet reactivity during therapy with inhibitors of cyclooxigenase or adenosine diphosphate receptors. Rational Pharmacother Card 2012; 8 (2): 168–2. Russian (Ломоносова А.А., Мазур Н.А., Золозова Е.А. и др. Остаточная реактивность тромбоцитов на терапии ингибиторами циклооксигеназы или рецепторов аденозиндифосфата. Рациональная фармакотерапия в кардиологии. 2012; 8 (2): 168–2).
16. Serebruany VL. Viewpoint: Paradoxial excess mortality in the PLATO trial should be independently verified. Thrombosis and Haemostasis 2011, 105: 752–9.

Н.А.Мазур, А.А.Ломоносова, Е.А.Золозова, Е.В.Саютина, В.В.Чигинева

ГБОУ ДПО РМАПО, Москва